Human mesenchymal stem cells alter the gene profile of monocytes from patients with Type 2 diabetes and end-stage renal disease

Written by Regenerative Medicine

In a Research Article exclusively free for members, Andrea F Wise et al. from Monash University (Australia) investigate investigated whether MSCs can modulate the phenotype of monocytes isolated from Type 2 diabetic patients with end-stage renal disease, and therefore have potential for therapeutic intervention. Diabetic nephropathy (DN) is a progressive kidney disease resulting from diabetes, caused by chronic inflammation, and owing to the lack of effective therapies available is the leading cause of end-stage renal disease (ESRD) worldwide. Although the infiltration of monocytes and monocyte-derived macrophages is a hallmark of diabetic kidney disease and the number of macrophages correlates with...

To view the full article, please register now for access

It's completely free